ANRO

NEUTRALEarnings

Alto Neuroscience, Inc.

2026-08-31

Price

$35.38

+0.71%

This is the 2026-08-31 snapshot — the signals and analysis for ANRO as of this single trading day.

View full ANRO research hub →

Score3.2Watchlist

Signals3/8 DNA0/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume1.8xvs 20d avg

Analysis

Alto Neuroscience (ANRO) is experiencing high-conviction price discovery, surging nearly 30% over the last month on the back of a Q2 earnings beat, a $100M capital raise, and the expansion of its ALTO-207 Phase 3 trial. Technical signals including a PERFECT_STACK and MARKET_LEADER confirm aggressive institutional accumulation, completely shrugging off recent geopolitical noise. With the macro regime firmly RISK_ON and credit spreads at an ultra-low 0.79%, the market environment heavily favors well-funded, clinical-stage biotechs like ANRO whose cash runway now extends to 2030.

Fired Signals

GOLDEN CROSSMARKET LEADERPERFECT STACK

Key Takeaways

Actionable Thesis: ANRO's technical breakout is fundamentally backed by an extended cash runway to 2030 and expanded ALTO-207 Phase 3 trials [2.1.2], making it a high-conviction momentum buy.
Key Risk: As a clinical-stage biotech, the stock remains highly sensitive to trial data delays or sudden shifts in the broader risk-on macro sentiment.
What to Watch: Monitor the $28.03 support level as a trailing stop and look for continued relative strength against the SPY amid geopolitical noise.

← Back to 2026-08-31 View Full ANRO History →Yahoo Finance &nearr;